Electroporation-mediated gene therapy

Expert Opinion on Drug Delivery

Volumn 4, Issue 5, 2007, Pages 561-571

  Isaka, Yoshitaka ^a   Imai, Enyu ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytokine; DNA vaccine; Electroporation; Erythropoietin; IL 12

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BLEOMYCIN; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; CISPLATIN; CYCLOSPORIN; DNA VACCINE; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FC RECEPTOR; FLT3 LIGAND; GAMMA INTERFERON RECEPTOR; GENE THERAPY AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; METHYL CPG BINDING PROTEIN 2; PLASMID DNA; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RECOMBINANT INTERLEUKIN 12; SIALIDASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNINDEXED DRUG;

ANTISENSE THERAPY; ARTHRITIS; AUTOIMMUNE DISEASE; BETA THALASSEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ELECTROPORATION; EVIDENCE BASED MEDICINE; GENE TARGETING; GENE THERAPY; GLOMERULONEPHRITIS; HEMOPHILIA; HUMAN; HYPERTENSION; IN VIVO STUDY; INFLAMMATORY DISEASE; INFLUENZA; KIDNEY; LIVER; MELANOMA; NEPHROTOXICITY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POLYCYTHEMIA; REVIEW; RNA INTERFERENCE; SKELETAL MUSCLE; SKIN; SOLID TUMOR; SUICIDE GENE THERAPY; TISSUE SPECIFICITY; UNSPECIFIED SIDE EFFECT; VACCINATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ELECTROPORATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; TISSUE DISTRIBUTION;

EID: 35148859893     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.4.5.561     Document Type: Review

References (118)

1. BLAESE RM, CULVER KW, MILLER AD et al.: T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science (1995) 270(5235):475-480.
2. PILARO AM, SERABIAN MA: Preclinical development strategies for novel gene therapeutic products. Toxicol. Pathol. (1999) 27(1):4-7.
3. NEUMANN E, SCHAEFER-RIDDER M, WANG Y, HOFSCHNEIDER PH: Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J. (1982) 1:841-845.
4. POTTER H: Electroporation in biology: methods, applications, and instrumentation. Anal. Biochem. (1988) 174(2):361-373.
5. TSONG TY: Electroporation of cell membranes. Biophys. J. (1991) 60(2):297-306.
6. ZIMMERMANN U: Electric field-mediated fusion and related electrical phenomena. Biochim. Biophys. Acta (1982) 694(3):227-277.
7. GOTHELF A, MIR LM, GEHL J: Electrochemotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat. Rev. (2003) 29(5):371-387.
8. HELLER R, JAROSZESKI M, ATKIN A et al.: In vivo gene electroinjection and expression in rat liver. FEBS Lett. (1996) 389:225-228.
9. NISHI T, YOSHIZATO K, YAMASHIRO S et al.: High-efficiency in vivo gene transfer using intraarterial plasmid DNA injection following in vivo electroporation. Cancer Res. (1996) 56(5):1050-1055.
10. ZAMPAGLIONE I, ARCURI M, CAPPELLETTI M et al.: In vivo DNA gene electro-transfer: a systematic analysis of different electrical parameters. J. Gene Med. (2005) 7(11):1475-1481.
11. MIR LM, BUREAU MF, GEHL J et al.: High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc. Natl. Acad. Sci. USA (1999) 96(8):4262-4267.
12. COSTER HG: A quantitative analysis of the voltage-current relationships of fixed charge membranes and the associated property of "punch-through". Biophys. J. (1965) 5(5):669-686.
13. ZIMMERMANN U, SCHULZ J, PILWAT G: Transcellular ion flow in Escherichia coli B and electrical sizing of bacterias. Biophys. J. (1973) 13(10):1005-1013.
14. BENZ R, ZIMMERMANN U: Pulse-length dependence of the electrical breakdown in lipid bilayer membranes. Biochim. Biophys. Acta (1980) 597(3):637-642.
15. BENZ R, ZIMMERMANN U: The resealing process of lipid bilayers after reversible electrical breakdown. Biochim. Biophys. Acta (1981) 640(1)169-178.
16. CHANG DC, REESE TS: Changes in membrane structure induced by electroporation as revealed by rapid-freezing electron microscopy. Biophys. J. (1990) 58(1):1-12.
17. KNUTSON JC, YEE D: Electroporation: parameters affecting transfer of DNA into mammalian cells. Anal. Biochem. (1987) 164(1):44-52.
18. BUREAU MF, GEHL J, DELEUZE V, MIR LM, SCHERMAN D: Importance of association between permeabilization and electrophoretic forces for intramuscular DNA electrotransfer. Biochim. Biophys. Acta (2000) 1474(3):353-359.
19. SATKAUSKAS S, ANDRE F, BUREAU MF, SCHERMAN D, MIKLAVCIC D, MIR LM: Electrophoretic component of electric pulses determines the efficacy of in vivo DNA electrotransfer. Hum. Gene Ther. (2005) 16(10):1194-1201.
20. SATKAUSKAS S, BUREAU MF, PUC M et al.: Mechanisms of in vivo DNA electrotransfer: respective contributions of cell electropermeabilization and DNA electrophoresis. Mol. Ther. (2002) 5(2):133-140.
21. LIU F, HESTON S, SHOLLENBERGER LM et al.: Mechanism of in vivo DNA transport into cells by electroporation: electrophoresis across the plasma membrane may not be involved. J. Gene Med. (2006) 8(3):353-361.
22. CHERNOMORDIK LV, SOKOLOV AV, BUDKER VG: Electrostimulated uptake of DNA by liposomes. Biochim. Biophys. Acta (1990) 1024(1):179-183.
23. XIE TD, SUN L, TSONG TY: Study of mechanisms of electric field-induced DNA transfection. I. DNA entry by surface binding and diffusion through membrane pores. Biophys. J. (1990) 58(1)13-19.
24. DRINKWATER NR, KLINEDINST DK: Chemically induced mutagenesis in a shuttle vector with a low-background mutant frequency. Proc. Natl. Acad. Sci. USA (1986) 83(10):3402-3406.
25. AIHARA H, MIYAZAKI J: Gene transfer into muscle by electroporation in vivo Nat. Biotechnol. (1998) 16:867-870.
26. BETTAN M, EMMANUEL F, DARTEIL R et al.: High-level protein secretion into blood circulation after electric pulse-mediated gene transfer into skeletal muscle. Mol. Ther. (2000) 2(3):204-210.
27. MURAMATSU T, ARAKAWA S, FUKAZAWA K et al.: In vivo gene electroporation in skeletal muscle with special reference to the duration of gene expression. Inc. J. Mol. Med. (2001) 7(1):37-42.
28. TONE CM, CARDOZA DM, CARPENTER RH, DRAGHIA-AKLI R: Long-term effects of plasmid-mediated growth hormone releasing hormone in dogs. Cancer Gene Ther. (2004) 11(5):389-396.
29. BABIUK LA, PONTAROLLO R, BABIUK S, LOEHR B, VAN DRUNEN LITTEL-VAN DEN HURK S: Induction of immune responses by DNA vaccines in large animals. Vaccine (2003) 21(7-8):649-658.
30. SCHEERLINCK JP, KARLIS J, TJELLE TE, PRESIDENTE PJ, MATHIESEN I, NEWTON SE: In vivo electroporation improves immune responses to DNA vaccination in sheep. Vaccine (2004) 22(13-14):1820-1825.
31. WU CJ, LEE SC, HUANG HW, TAO MH: In vivo electroporation of skeletal muscles Increases the efficacy of Japanese encephalitis virus DNA vaccine. Vaccine (2004) 22(11-12):1457-1464.
32. PERETZ Y, ZHOU ZF, HALWANI F, PRUD'HOMME GJ: In vivo generation of dendritic cells by intramuscular codelivery of FLT3 ligand and GM-CSF plasmids. Mol Ther. (2002) 6(3):407-414.
33. SHIMAO K, TAKAYAMA T, ENOMOTO K et al.: Cancer gene therapy using in vivo electroporation of Flt3-ligand. Intern. J. Oncol. (2005) 27(2):457-463.
34. LONG YC, JAICHANDRAN S, HO LP, TIEN SL, TAN SY, KON OL: FVIII gene delivery by muscle electroporation corrects murine hemophilia A. J. Gene. Med. (2005) 7(4):494-505.
35. RIZZUTO G, CAPPELLETTI M, MAIONE D et al.: Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc. Natl. Acad. Sci. USA (1999) 96(11):6417-6422.
36. PAYEN E, BETTAN M, ROUYER-FESSARD P, BEUZARD Y, SCHERMAN D: Improvement of mouse β-thalassemia by electrotransfer of erythropoietin cDNA. Exp. Hematol. (2001) 29(3):295-300.
37. ATAKA K, MARUYAMA H, NEICHI T, MIYAZAKI J, GEJYO F: Effects of erythropoietin-gene electrotransfer in rats with adenine-induced renal failure. Am. J. Nephrol. (2003) 23(5):315-323.
38. MARUYAMA H, ATAKA K, GEJYO F et al.: Long-term production of erythropoietin after electroporation-mediated transfer of plasmid DNA into the muscles of normal and uremic rats. Gene Ther. (2001) 8(6):461-468.
39. FATTORI E, CAPPELLETTI M, ZAMPAGLIONE I et al.: Gene electro-transfer of an improved erythropoietin plasmid in mice and non-human primates. J. Gene Med. (2005) 7(2):228-236.
40. TERADA Y, TANAKA H, OKADO T et al.: Efficient and ligand-dependent regulated erythropoietin production by naked DNA injection and in vivo electroporation. Am. J. Kidney Dis. (2001) 38(4 Suppl. 1):S50-S53.
41. TERADA Y, TANAKA H, OKADO T et al.: Ligand-regulatable erythropoietin production by plasmid injection and in vivo electroporation. Kidney Int. (2002) 62(6): 1966-1976.
42. MARUYAMA H, HIGUCHI M, HIGUCHI N et al.: Post-secretion neutralization of transgene-derived effect: soluble erythropoietin receptor/IgG1Fc expressed in liver neutralizes erythropoietin produced in muscle. J. Gene Med. (2004) 6(2):228-237.
43. TANG DC, DEVIT M, JOHNSTON SA: Genetic immunization is a simple method for eliciting an immune response. Nature (1992) 356(6365):152-154.
44. ULMER JB, DONNELLY JJ, PARKER SE et al.: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 259(5102):1745-1749.
45. VAN DRUNEN LITTEL-VAN DEN HURK S, BABIUK SL, BABIUK LA: Strategies for improved formulation and delivery of DNA vaccines to veterinary target species. Immunol. Rev. (2004) 199:113-125.
46. WIDERA G, AUSTIN M, RABUSSAY D et al.: Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol. (2000) 164(9):4635-4640.
47. KIRMAN JR, SEDER BA: DNA vaccination: the answer to stable, protective T-cell memory? Curr. Opin. Immunol. (2003) 15(4):471-476.
48. LEE AH, SUH YS, SUNG JH, YANG SH, SUNG YC: Comparison of various expression plasmids for the induction of immune response by DNA immunization. Mol. Cells (1997) 7(4):495-501.
49. PRUD'HOMME GJ: DNA vaccination against tumors. J. Gene Med. (2005) 7(1):3-17.
50. GRONEVIK E, VON STEYERN FV, KALHOVDE JM, TJELLE TE, MATHIESEN I: Gene expression and immune response kinetics using electroporation-mediated DNA delivery to muscle. J. Gene Med. (2005) 7(2):218-227.
51. TOLLEFSEN S, VORDERMEIER M, OLSEN I et al.: DNA injection in combination with electroporation: a novel method for vaccination of farmed ruminants. Scand. J. Immunol. (2003) 57(3):229-238.
52. CHEN J, FANG F, LI X, CHANG H, CHEN Z: Protection against influenza virus infection in BALB/c mice immunized with a single dose of neuraminidase-expressing DNAs by electroporation. Vaccine (2005) 23(34):4322-4328.
53. PRUD'HOMME GJ, LAWSON BR, CHANG Y, THEOFILOPOULOS AN: Immunotherapeutic gene transfer into muscle. Trends Immunol. (2001) 22(3):149-155.
54. PRUD'HOMME GJ, LAWSON BR, THEOFILOPOULOS AN: Anticytokine gene therapy of autoimmune diseases. Expert Opin. Biol. Ther. (2001) 1(3):359-373.
55. LAWSON BR, PRUD'HOMME GJ, CHANG Y et al.: Treatment of murine lupus with cDNA encoding IFN-γR/Fc. J. Clin. Investig. (2000) 106(2):207-215.
56. JEONG JG, KIM JM, HO SH, HAHN W, YU SS, KIM S: Electrotransfer of human IL-1Ra into skeletal muscles reduces the incidence of murine collagen-induced arthritis. J. Gene Med. (2004) 6(10):1125-1133.
57. KIM JM, HO SH, HAHN W et al.: Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein. Gene Ther. (2003) 10(15):1216-1224.
58. NAKAMURA H, ISAKA Y, TSUJIE M et al.: Electroporation-mediated PDGF receptor-IgG chimera gene transfer ameliorates experimental glomerulonephritis. Kidney Int. (2001) 59(6):2134-2145.
59. XIN J, HOMMA T, MATSUSAKA T et al.: Suppression of cyclosporine A nephrotoxicity in vivo by transforming growth factor β receptor-immunoglobulin G chimeric protein. Transplantation (2004) 77(9):1433-1442.
60. LEE PY, CHESNOY S, HUANG L: Electroporatic delivery of TGF-β1 gene works synergistically with electric therapy to enhance diabetic wound healing in db/db mice. J. Invest. Dermatol. (2004) 123(4):791-798.
61. XUE F, TAKAHARA T, YATA Y et al.: Attenuated acute liver injury in mice by naked hepatocyte growth factor gene transfer into skeletal muscle with electroporation. Gut (2002) 50(4):558-562.
62. MIZUI M, ISAKA Y, TAKABATAKE Y et al.: Electroporation-mediated HGF gene transfer ameliorated cyclosporine nephrotoxicity. Kidney Intern. (2004) 65(6):2041-2053.
63. UMEDA Y, MARUI T, MATSUNO Y et al.: Skeletal muscle targeting in vivo electroporation-mediated HGF gene therapy of bleomycin-induced pulmonary fibrosis in mice. Lab. Invest. (2004) 84(7):836-844.
64. PRADAT PF, FINIELS F, KENNEL P et al.: Partial prevention of cisplatin-induced neuropathy by electroporation-mediated nonviral gene transfer. Hum. Gene Ther. (2001) 12(4):367-375.
65. REBERSEK M, CUFER T, CEMAZAR M, KRANJC S, SERSA G: Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer. Anticancer Drugs (2004) 15(6):593-597.
66. BELEHRADEK M, DOMENGE C, LUBOINSKI B, ORLOWSKI S, BELEHRADEK J JR. MIR LM: Electrochemotherapy, a new antitumor treatment. First clinical Phase I - II trial. Cancer (1993) 72(12):3694-3700.
67. MIR LM, DEVAUCHELLE P, QUINTIN-COLONNA F et al.: First clinical trial of cat soft-tissue sarcomas treatment by electrochemotherapy. Br. J. Cancer (1997) 76(12):1617-1622.
68. LUCAS ML, HELLER L, COPPOLA D, HELLER R: IL-12 plasmid delivery by in vivo electroporation for the successful treatment of established subcutaneous B16. F10 melanoma. Mol. Ther. (2002) 5(6):668-675.
69. LUCAS ML, HELLER R: Immunomodulation by electrically enhanced delivery of plasmid DNA encoding IL-12 to murine skeletal muscle. Mol. Ther. (2001) 3(1):47-53.
70. CICHON T, JAMROZY L, GLOGOWSKA J, MISSOL-KOLKA E, SZALA S: Electrotransfer of gene encoding endostatin into normal and neoplastic mouse tissues: inhibition of primary tumor growth and metastatic spread. Cancer Gene Ther. (2002) 9(9):771-777.
71. SHIBATA MA, MORIMOTO J, OTSUKI Y: Suppression of murine mammary carcinoma growth and metastasis by HSVtk/GCV gene therapy using in vivo electroporation. Cancer Gene Ther. (2002) 9(1):16-27.
72. LI S, ZHANG L, TORRERO M, CANNON M, BARRET R: Administration route- and immune cell activation-dependent tumor eradication by IL12 electrotransfer. Mol. Ther. (2005) 12(5):942-949.
73. YAMASHITA Y, SHIMADA M, TANAKA S, OKAMAMOTO M, MIYAZAKI J, SUGIMACHI K: Electroporation-mediated TNF-related apoptosis-inducing ligand (TRAIL)/ Apo2L gene therapy for hepatocellular carcinoma. Hum. Gene Ther. (2002) 13(2):275-286.
74. IVANOV MA, LAMRIHI B, SZYF M, SCHERMAN D, BIGEY P: Enhanced antitumor activity of a combination of MBD2-antisense electrotransfer gene therapy and bleomycin electrochemotherapy. J. Gene Med. (2003) 5(10)893-899.
75. LI S, XIA X, ZHANG X, SUEN J: Regression of tumors by IFN-α electroporation gene therapy and analysis of the responsible genes by cDNA array. Gene Ther. (2002) 9(6):390-397.
76. KISHIDA T, ASADA H, SATOH E et al.: In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Ther. (2001) 8(16):1234-1240.
77. TSUJIE M, ISAKA Y, NAKAMURA H, IMMAI E, HORI M: Electroporation-mediated gene transfer that targets glomeruli. J. Am. Soc. Nephrol. (2001) 12(5)949-954.
78. ISAKA Y, NAKAMURA H, MIZUI M et al.: DNAzyme for TGF-β suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int. (2004) 66(2):586-590.
79. TAKABATAKE Y, ISAKA Y, MIZUI M et al.: Exploring RNA interference as a therapeutic strategy for renal disease. Gene Ther. (2005) 12(12):965-973.
80. MIZUI M, ISAKA Y, TAKABATAKE Y et al.: Transcription factor Ets-1 is essential for mesangial matrix remodeling. Kidney Int. (2006) 70(2):298-305.
81. YAZAWA K, ISAKA Y, TAKAHARA S et al.: Direct transfer of hepatocyte growth factor gene into kidney suppresses closporin A nephrotoxicity in rats. Nephrol. Dial. Transplant. (2004) 19(4):812-816.
82. NAKAMURA H, ISAKA Y, TSUJIE M et al.: Introduction of DNA enzyme for Egr-1 into tubulointerstitial fibroblasts by electroporation reduced interstitial -smooth muscle actin expression and fibrosis in unilateral ureteral obstruction (UUO) rats. Gene Ther. (2002) 9(8):495-502.
83. TSUJIE M, ISAKA Y, ANDO Y et al.: Gene transfer targeting interstitial fibroblasts by the artificial viral envelope-type hemagglutinating virus of Japan liposome method. Kidney Int. (2000) 57(5):1973-1980.
84. FUJII N, ISAKA Y, TAKABATAKE Y et al.: Targeting of interstitial cells using a simple gene-transfer strategy. Nephrol. Dial. Transplant. (2006) 21(10):2745-2753.
85. FAVRE D, PROVOST N, BLOUIN V et al.: Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. Mol. Ther. (2001) 4(6):559-566.
86. NATHWANI AC, DAVIDOFF AM, HANAWA H et al.: Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood (2002) 100(5): 1662-1669.
87. REYNOLDS PN, HOLMES MD, ADACHI Y, KALIBEROVA L, CURIEL DT: A novel system for mitigation of ectopic transgene expression induced by adenoviral vectors. Gene Ther. (2001) 8(16):1271-1275.
88. THOMA C, WIELAND S, MORADPOUR D et al.: Ligand-mediated retargeting of recombinant adenovirus for gene transfer in vivo. Gene Ther. (2000) 7(12):1039-1045.
89. LIU F, HUANG L: Improving plasmid DNA-mediated liver gene transfer by prolonging its retention in the hepatic vasculature. J. Gene Med. (2001) 3(6):569-576.
90. LIU F, SONG Y, LIU D: Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. (1999) 6(7):1258-1266.
91. ZHANG G, BUDKER V, WOLFF JA: High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. (1999) 10(10):1735-1737.
92. JAROSZESKI MJ, COPPOLA D, POTTINGER C, BENSON K, GILBERT RA, HELLER R: Treatment of hepatocellular carcinoma in a rat model using electrochemotherapy. Eur. J. Cancer (2001) 37(3):422-430.
93. HARADA N, SHIMADA M, OKANO S et al.: IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice. J. Immunol. (2004) 173(11):6635-6644.
94. MURAMATSU T, ITO N, TAMAOKI N, ODA H, PARK HM: In vivo gene electroporation confers nutritionally-regulated foreign gene expression in the liver. Int. J. Mol. Med. (2001) 7(1):61-66.
95. SAKAI M, NISHIKAWA M, THANAKETPAISARN O, YAMASHITA F, HASHIDA M: Hepatocyte-targeted gene transfer by combination of vascularly delivered plasmid DNA and in vivo electroporation. Gene Ther. (2005) 12(7):607-616.
96. PENG J, ZHAO Y, MAI J et al.: Inhibition of hepatitis B virus replication by various RNAi constructs and their pharmacodynamic properties. J. Gen. Virol. (2005) 86(Part 12):3227-3234.
97. ZHANG L, NOLAN E, KREITSCHITZ S, RABUSSAY DP: Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. Biochim. Biophys. Acta (2002) 1572(1):1-9.
98. DRABICK JJ, GLASSPOOL-MALONE J, KING A, MALONE RW: Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Mol. Ther. (2001) 3(2):249-255.
99. GLASSPOOL-MALONE J, SOMIARI S, DRABICK JJ, MALONE RW: Efficient nonviral cutaneous transfection. Mol. Ther. (2000) 2(2):140-146.
100. MARTI G, FERGUSON M, WANG J et al.: Electroporative transfection with KGF-1 DNA improves wound healing in a diabetic mouse model. Gene Ther. (2004) 11(24):1780-1785.
101. MEDI BM, HOSELTON S, MAREPALLI RB, SINGH J: Skin targeted DNA vaccine delivery using electroporation in rabbits. I: efficacy. Int. J. Pharmaceut. (2005) 294(1-2):53-63.
102. ISHIKAWA H, TAKANO M, MATSUMOTO N et al.: Effect of GDNF gene transfer into axotomized retinal ganglion cells using in vivo electroporation with a contact lens-type electrode. Gene Ther. (2005) 12(4):289-298.
103. MATSUDA T, CEPKO CL: Controlled expression of transgenes introduced by in vivo electroporation. Proc. Natl. Acad. Sci. USA (2007) 104(3):1027-1032.
104. MO X, YOKOYAMA A, OSHITARI T et al.: Rescue of axotomized retinal ganglion cells by BDNF gene electroporation in adult rats. Invest. Ophthalmol. Vis. Sci. (2002) 43(7):2401-2405.
105. DEZAWA M, TAKANO M, NEGISHI H, MO X, OSHITARI T, SAWADA H: Gene transfer into retinal ganglion cells by in vivo electroporation: a new approach. Micron (2002) 33(1):1-6.
106. GAZDHAR A, FACHINGER P, VAN LEER C et al.: Gene transfer of hepatocyte growth factor by electroporation reduces bleomycin-induced lung fibrosis. Am. J. Physiol. (2007) 292(2):L529-L536.
107. SEIDLER RW, ALLGAUER S, AILINGER S et al.: In vivo human MCP-1 transfection in porcine arteries by intravascular electroporation. Pharm. Res. (2005) 22(10):1685-1691.
108. OTANI M, YOSHIDA M, IWASHITA H et al.: Electroporation-mediated muscarinic M3 receptor gene transfer into rat urinary bladder. Int. J. Urol. (2004) 11(11):1001-1008.
109. COLOMBO MP, TRINCHIERI G: Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev. (2002) 13(2):155-168.
110. RAKHMILEVICH AL, TIMMINS JG, JANSSEN K, POHLMANN EL, SHEEHY MJ, YANG NS: Gene gun-mediated IL-12 gene therapy induces antitumor effects in the absence of toxicity: a direct comparison with systemic IL-12 protein therapy. J. Immunother. (1999) 22:135-144.
111. HEINZERLING L, BURG G, DUMMER R et al.: Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy. Hum. Gene Ther. (2005) 16(1):35-48.
112. HELLER L, MERKLER K, WESTOVER J et al.: Evaluation of toxicity following electrically mediated interleukin-12 gene delivery in a B16 mouse melanoma model. Clin. Cancer Res. (2006) 12(10):3177-3183.
113. YEN HH, SCHEERLINCK JP: Co-delivery of plasmid-encoded cytokines modulates the immune response to a DNA vaccine delivered by in vivo electroporation. Vaccine (2007) 25(14): 2575-2582.
114. ISAKA Y, YAMADA K, TAKABATAKE Y et al.: Electroporation-mediated HGF gene transfection protected the kidney against graft injury. Gene Ther. (2005) 12(10):815-820.
115. KOBAYASHI S, DONO K, TAKAHARA S et al.: Electroporation-mediated ex vivo gene transfer into graft not requiring injection pressure in orthotopic liver transplantation. J. Gene Med. (2003) 5(6):510-517.
116. KOBAYASHI S, DONO K, TANAKA T et al.: Gene transfer into the liver by plasmid injection into the portal vein combined with electroporation. J. Gene Med. (2003) 5(3):201-208.
117. PALMER TD, ROSMAN GJ, OSBORNE WR, MILLER AD: Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes. Proc. Natl. Acad. Sci. USA (1991) 88(4):1330-1334.
118. YAMAMOTO S, YAMANO T, TANAKA M et al.: A novel combination of suicide gene therapy and histone deacetylase inhibitor for treatment of malignant melanoma. Cancer Gene Ther. (2003) 10(3):179-186.